作者
David D Berg, Pardeep S Jhund, Kieran F Docherty, Sabina A Murphy, Subodh Verma, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Olof Bengtsson, Piotr Ponikowski, Mikaela Sjöstrand, Scott D Solomon, John JV McMurray, Marc S Sabatine
发表日期
2021/5/1
期刊
JAMA cardiology
卷号
6
期号
5
页码范围
499-507
出版商
American Medical Association
简介
Importance
Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF). However, clinical inertia often underlies deferred initiation of effective therapies.
Objective
To examine timing of onset of clinical benefit with dapagliflozin and magnitude as a function of proximity to prior HF hospitalization.
Design, Setting, and Participants
This is a secondary analysis of a completed multinational trial. The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure trial was a double-blind, placebo-controlled randomized clinical trial of dapagliflozin in patients with chronic HFrEF (n = 4744). From February 2017 to August 2018, the study enrolled patients in New York Heart Association classes II through IV and with left ventricular ejection fraction of 40% or less; the median (range) follow-up time was 18.2 (0-27.8 …
学术搜索中的文章
DD Berg, PS Jhund, KF Docherty, SA Murphy, S Verma… - JAMA cardiology, 2021